Viret Named CFO at Blade Therapeutics
22 March 2021 - - US-based biopharmaceutical company Blade Therapeutics, Inc has appointed Jean-Frédéric Viret, Ph.D., as chief financial officer effective immediately, the company said.

In his role, Viret will lead Blade's finance and accounting functions, as well as investor relations and corporate communications.

Viret has nearly two decades of corporate finance experience within the life sciences industry, most recently serving as CFO with Coherus BioSciences, Inc. (NASDAQ: CHRS), a commercial-stage biopharmaceutical company that he joined in 2014.

He has previous experience in CFO roles during tenures at several public and privately held biopharmaceutical and diagnostics companies.

In addition to a Ph.D. in Plant Molecular Biology from Université Louis Pasteur (Strasbourg), Dr. Viret has a B.S. in Engineering from the Institut National Polytechnique de Lorraine and an M.B.A. from Cornell University.

He was a visiting fellow at Harvard University and a postdoctoral fellow at the Massachusetts Institute of Technology.

Blade Therapeutics is a private biopharmaceutical company founded on a goal of advancing the treatment of debilitating, incurable fibrotic diseases.

The company is an expert in novel biological pathways including autotaxin / lysophosphatidic acid and calpain biology that are foundational to cell and tissue damage responses leading to fibrosis.

Blade is advancing a robust pipeline of potential first-in-class investigational therapies for diseases of lung, liver and heart fibrosis, as well as neurodegenerative diseases.

This includes multiple small-molecule direct inhibitors of autotaxin / LPA and dimeric calpains that offer distinct but complementary anti-fibrotic mechanisms.